Search Within

Aaron David Goldberg

Formats
  1. Meeting Abstract (69)
  2. Journal Article (32)
  3. Research Letter (6)
  4. Correspondence (4)
  5. Editorial (3)
  6. Review (2)
  7. Book Section (1)
Groups
  1. Adult Leukemia (117)
  2. Center for Hematologic Malignancies (117)
  3. Department of Medicine (117)
  4. Hematologic Malignancies, Division of (117)
  5. Weinberg Fellows (117)
  6. Hematology-Oncology Fellows (55)

More Groups

People
  1. Martin Tallman (49)
  2. Eytan Stein (43)
  3. Christopher Famulare (38)
  4. Andriy Derkach (22)
  5. Ross Levine (21)
  6. Jan Bewersdorf (20)

More People

Years
  1. 2025 (4)
  2. 2024 (20)
  3. 2023 (20)
  4. 2022 (15)
  5. 2021 (15)
  6. 2020 (15)

More Years

Publications
  1. Blood (63)
  2. Leukemia and Lymphoma (8)
  3. American Journal of Hematology (6)
  4. Blood Advances (5)
  5. Journal of Clinical Oncology (5)
  6. Haematologica (4)

More Publications

Publishers
  1. American Society of Hematology (68)
  2. Taylor & Francis Group (8)
  3. American Society of Clinical Oncology (6)
  4. John Wiley & Sons, Inc. (6)
  5. Elsevier Inc. (4)
  6. Ferrata Storti Foundation (4)

More Publishers

Results (117)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational status
    Correspondence

    Badar, T.; Foran, J. M.; Bewersdorf, J. P.; Wang, Y. H.; Coltoff, A.; El Kettani, M.; Shah, K.; Denis Oliva, F.; Lin, C.; Jamy, O.; more...
    British Journal of Haematology (2025)

    Fulltext@MSK | Save
  • Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs
    Journal Article

    Burton, H.; Boussi, L.; Nemirovsky, D.; Derkach, A.; Ciervo, J.; Famulare, C.; Chin, K. K.; Valtis, Y.; Yisraeli Salman, M.; Patel, K.; more...
    Cancer (2025)

    Fulltext@MSK | Save
  • Venetoclax–azacitidine versus azacitidine for the treatment of primary refractory or first relapsed acute myeloid leukemia. An IPC-DATAML-MSKCC retrospective study
    Correspondence

    Petit, C.; Higue, J.; Acheaibi, Z.; Gilhodes, J.; Hospital, M. A.; Devillier, R.; Bewersdorf, J.; Goldberg, A. D.; Pigneux, A.; Vey, N.; more...
    American Journal of Hematology (2025)

    Fulltext@MSK | Save
  • HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML
    Journal Article

    Chin, K. K.; Derkach, A.; Famulare, C.; Gupta, G. K.; Borge, P. D.; Geyer, M.; Goldberg, A. D.; Haque, T.; Park, J. H.; Roeker, L. E.; more...
    Leukemia and Lymphoma (2025)

    Fulltext@MSK | Save
  • Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia
    Journal Article

    Chin, K. K.; Valtis, Y.; Derkach, A.; Yisraeli Salman, M.; Boussi, L.; Ciervo, J.; Geyer, M. B.; Park, J. H.; Tallman, M. S.; Glass, J. L.; more...
    Blood Neoplasia (2024)

    Fulltext@MSK | Save
  • A multi-site break through cancer trial: Phase II study investigating dual inhibition of BCL2 and menin in AML MRD using the combination of venetoclax and revumenib (trial in progress)
    Meeting Abstract

    Issa, G. C.; Ambinder, A. J.; Xiao, W.; Manalis, S.; Shalek, A. K.; Gondek, L. P.; Kentsis, A.; Short, N. J.; Daver, N.; Ning, J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Results from the Great Britain AML real world evidence (ARC) initiative - A centre-based chart review study to assess treatment outcomes of venetoclax for the treatment of acute myeloid leukemia
    Meeting Abstract

    O'Nions, J.; Errico, G.; Floro, L.; Murthy, V.; Sweeney, C.; Kaur, H.; Mohite, U.; Ayto, R.; Alvares, C.; Goldberg, A. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML
    Meeting Abstract

    Chin, K. K.; Derkach, A.; Famulare, C.; Gupta, G.; Borge, P.; Geyer, M. B.; Goldberg, A. D.; Haque, T.; Park, J. H.; Roeker, L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Venetoclax-based therapy versus intensive chemotherapy followed by allogeneic-stem cell transplantation for high-risk elderly acute myeloid leukemia
    Meeting Abstract

    Iat, A.; Bewersdorf, J. P.; Gilhodes, J.; Liu, Y.; Shallis, R. M.; Boussi, L.; Zucenka, A.; Bystrom, R. P.; Deangelo, D. J.; Berton, G.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Roeker, L.; Mato, A. R.; Zelenetz, A. D.; Park, J. H.; Geyer, M. B.; Derkach, A.; Nemirovsky, D.; Islam, P.; Falchi, L.; Palomba, M. L.; more...
    Blood (2024)

    Fulltext@MSK | Save